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Summary objectives To estimate the proportion of all-cause adult patient attrition from antiretroviral therapy
(ART) programs in service delivery settings in sub-Saharan Africa through 36 months on treatment.
methods We identiﬁed cohorts within Ovid Medline, ISI Web of Knowledge, Cochrane Database of
Systematic Reviews and four conference abstract archives. We summarized retention rates from studies
describing observational cohorts from sub-Saharan Africa reporting on adult HIV 1- infected patients
initiating ﬁrst-line three-drug ART. We estimated all-cause attrition rates for 6, 12, 18, 24, or 36 months
after ART initiation including patients who died or were lost to follow-up (as deﬁned by the author), but
excluding transferred patients.
results We analysed 33 sources describing 39 cohorts and 226 307 patients. Patients were more likely
to be female (median 65%) and had a median age at initiation of 37 (range 34–40). Median starting CD4
count was 109 cells⁄mm
3. Loss to follow-up was the most common cause of attrition (59%), followed
by death (41%). Median attrition at 12, 24 and 36 months was 22.6% (range 7%–45%), 25% (range
11%–32%) and 29.5% (range 13%–36.1%) respectively. After pooling data in a random-effects meta-
analysis, retention declined from 86.1% at 6 months to 80.2% at 12 months, 76.8% at 24 months and
72.3% at 36 months. Adjusting for variable follow-up time in a sensitivity analysis, 24 month retention
was 70.0% (range: 66.7%–73.3%), while 36 month retention was 64.6% (range: 57.5%–72.1%).
conclusions Our ﬁndings document the difﬁculties in retaining patients in care for lifelong treatment,
and the progress being made in raising overall retention rates.
keywords antiretroviral therapy, attrition, retention, sub-Saharan Africa, systematic review, human
immuno-deﬁciency virus
Introduction
Although a great deal of research on daily adherence to
antiretroviral therapy (ART) in sub-Saharan Africa has
been published, long-term retention of patients in treat-
ment programs has received comparatively less attention.
ART has clearly been shown to be effective in reducing
mortality among those who remain in treatment and
adhere to therapy (Egger et al. 2002; Coetzee et al. 2004;
Ivers et al. 2005; Laurent et al. 2005; Lawn et al. 2005),
but under programmatic conditions, not all patients remain
in treatment. In addition to known mortality while in care,
some proportion of patients drop out of treatment
programs and do not restart care elsewhere (Brinkhof et al.
2009; Fox et al. 2010). These patients are at high risk of
morbidity and death within a short time. A valid measure
for assessing the long-term success of ART programs
should thus incorporate both mortality and loss to follow-
up. In recent years, this measure has often been reported as
the rate of retention, or the proportion of patients
remaining alive and on ART at various time points after
treatment initiation.
In 2007 we published the ﬁrst systematic review of
retention rates in cohorts in non-research settings in sub-
Saharan Africa. In that review we demonstrated that,
among over 74 000 patients representing 13 countries, the
proportion of patients alive and on ART 2 years after
initiation was approximately 60% (Rosen et al. 2007).
The ﬁndings raised concern about high rates of attrition
under programmatic conditions and suggested that more
attention was needed to maintaining high rates of patient
retention in both the months immediately following
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et al. 2008), as well as over the whole course of patients’
lives.
Since 2007, a number of publications have reported
retention experience in cohorts not included in the earlier
systematic review or reported on a longer duration of
follow-up of cohorts previously included. In this paper, we
present an updated systematic review of information
published between mid-2007 and mid-2009. We reviewed
recent data on retention and estimated the rate of all-cause
adult patient attrition from ART programs implemented
in service delivery settings in sub-Saharan Africa to
determine whether rates of retention have changed since
our initial estimates and to extend the previous estimates,
which covered 24 months of follow-up, through
36 months.
Methods
To allow comparison between this review and the previous
one, we maintained a similar methodology for this analysis
as in our earlier review.
Search strategy
The current analysis included studies describing the
results of observational cohort data from sub-Saharan
Africa which reported on all adult HIV 1- infected
patients who initiated ﬁrst-line three drug combination
ART, including those who discontinued treatment for any
reason. We included cohorts from any facility, whether
public, nongovernmental, or private, as long as they
treated the general population using standard therapy.
We excluded clinical trials and clinics serving specialized
populations, such as workforces. To avoid double-
counting, we excluded reports of pooled data where it
appeared that there was substantial overlap with patients
also included in single-cohort reports. We required
information beginning at ART initiation and a minimum,
mean, or median follow-up of 6 full months (26 weeks).
In some cases the average follow-up was not clearly
speciﬁed but it could either be calculated from informa-
tion provided or determined that it must be greater than
6 months. In cases where a cohort reported >50%
retention at the last time point reported to, but no
median duration of follow-up, the last time point
reported to was used as the median. Reports had to
include all-cause attrition rates for at least one of 6, 12,
18, 24, or 36 months after ART initiation. Studies that
did not report on these time points but did provide
enough information to calculate one of these rates were
also included. When possible, children and non-naı ¨ve
patients were excluded.
To identify studies for the current analysis, we searched
Ovid Medline 2007-week 2, August 2009, ISI Web of
Knowledge 2007-August 26, 2009 and Cochrane Database
of Systematic Reviews 2nd quarter 2009) and four
conference abstract archives (Conference on Retroviruses
and Opportunistic Infections 2008–2009 International
AIDS Conference 2007–2009, HIV Implementers Meeting
2008–2009 and International Association of Physicians in
AIDS Care 3rd Conference on Treatment Adherence). The
search in Medline, ISI, and the Cochrane Database
combined the terms ‘antiretroviral’ and ‘Africa’ with any
one of the following: retention⁄attrition⁄adherence⁄mor-
tality⁄loss to follow-up⁄efﬁcacy⁄evaluation or the term
‘antiretroviral’ and ‘developing country’ with either
‘adherence’ or ‘mortality’. Conference abstracts were
searched for any of the terms ‘attrition’ ‘retention’ or ‘lost
to follow-up’ except for the IAPAC conference in which all
abstracts were scanned.
SR identiﬁed the eligibility of all abstracts and journal
articles that met our initial search terms and MF con-
ﬁrmed eligibility. For each study identiﬁed for inclusion we
used a standard data extraction form to collect the
relevant data. In cases where multiple reports described the
same cohort, the one reporting to the longest time point
or with the most complete information was used.
Deﬁnitions
We deﬁned attrition from ART programs to include
patients who died or were lost to follow-up. We deﬁned
retention to be the opposite of attrition (i.e. 1 – attrition).
As reporting of patients who were still in care but had
stopped taking ARVs was variable, we did not exclude
these patients from the total retained in care. We accepted
the varying deﬁnitions used in the reports for loss to
follow-up and provide these deﬁnitions in Table 1. We
excluded patients who were transferred to another facility
from both the numerator and denominator of calculations
of retention as we could not assess their outcomes.
Statistical methods
We ﬁrst described each cohort and summarized its demo-
graphic and clinical characteristics by weighting the
reported values by the sample size. We plotted the reported
crude retention rates from each study at up to ﬁve time
points: 6, 12, 18, 24 and 36 months. When retention rates
were reported at time points different from those listed
above or only for the median duration of follow-up, we
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ª 2010 Blackwell Publishing Ltd, 15 (Suppl. 1), 1–15 5applied the reported rates to the time point to which they
were closest. For each study we calculated simple retention
proportions (%RT) at each time point t as:
%RTt¼ I0   Tt   Dt   LTFUt ðÞ = I0   Tt ðÞ
where I0 is all patients initiated on ART at the site; Tt is
all patients transferred out of care by time t; Dt is all
patients who died by time t; and LTFUt is all patients
lost to follow-up by time t. This is the proportion of all
patients initiated who did not transfer out of care who
are still alive and in care at the end of the follow-up
period.
In cases where the ﬁrst time point for which a study
reported retention rates was later than 6 months after
treatment initiation (25 studies representing 42 observa-
tions) we imputed the earlier missing time points.
Because rates of attrition are unlikely to be constant over
time (i.e. a linear decline), but rather likely to show a
sharp decline over the ﬁrst 6-months in care and level
out sometime after 1 year, we ﬁrst ﬁt a linear random-
effects regression model using all the data available on
current retention as a function of time, time squared,
and time cubed with a random intercept for each study.
The cubic form had a better ﬁt than linear, quadratic, or
half root forms. We then took the resulting predicted
curve and calculated the proportion of the total 36-
month attrition that was expected to have occurred by
each time period, with the constraint that retention could
not increase over time. In this model, of total retention
by 36 months, cumulatively 56% occurred by 6 months,
83% occurred by 12 months, 91% occurred by
18 months, 96% occurred by 24 months and 100%
occurred by 36 months. This information was used to
calculate the % retention at earlier missing time points
as:
%RTi ¼ 100%  ½ %TATi  ð 1   %RT1Þ 
where %RTi is the missing retention rate at month ti,
100% and %RT1 are the two reported retention rates at
baseline and time t1 that bound %RTi (i.e. 0 < ti <t 1),
and %TATi is the % of total attrition up to the ﬁrst
time period reported (i.e. %RT1) that occurred by time
ti. For example, if the ﬁrst retention proportion
reported was 80% at 12 months, the percent of total
attrition up to 12 months that occurred by 6 months
would be:
%TAT6 ¼½ 0:56=ð0:83Þ  ¼ 0:675
meaning that 67.5% of the total 20% attrition by
12 months occurred by 6-months. We would then estimate
the 6- month retention proportion to be:
%RT6 ¼ 1  ½ 0:675  ð 1   0:8Þ 
¼ 1  ð 0:675   0:2Þ¼0:865
For all time periods after the ﬁrst reported retention
proportion, if at least two non-consecutive time points of
interest were reported but the study did not give retention
proportions at one or more of the time points in between,
we interpolated proportions (%RTi) for the missing time
points as a linear decline:
%RTi ¼ %RT1  ð %RT1   %RT2Þ ½ ð ti   t1Þ=ðt2   t1Þ 
where %RTi is the interpolated retention proportion at
month ti and %RT1 and %RT2 are the two reported
retention proportions at months t1 and t2 that bound %RTi
(i.e. t1 <t i <t 2). This was carried out for seven of the
studies representing eight imputations.
As we previously demonstrated a relationship between
duration of follow-up and reported retention rates (Rosen
et al. 2007) (e.g. studies reporting only 6 months of follow-
up on average reported lower retention at 6 months than
the reported 6 month retention in studies reporting to 12
or 24 months), we ﬁrst described retention rates in the
current dataset by plotting them over time grouped by
duration of reporting. We display retention rates at 6, 12,
24 and 36 months using forest plots to allow for visual-
ization of the distribution of retention rates at each time
point. We then summarized these rates using random-
effects meta-analysis (Egger et al. 2001) using a Freeman
& Tukey (1950) arc-sin transformation of the retention
proportions and standard errors and presented point
estimates of retention and corresponding 95% conﬁdence
intervals.
To explore the impact of duration of reporting on
overall retention, we projected the path of retention rates
by extrapolating retention rates through 3 years
(36 months) for all studies from their time of last
reporting using three methods. We calculated a best-case
scenario using last observation carried forward from the
last time point reported through 3 years. We calculated a
worst-case scenario by assuming that the attrition rates
continued along the linear slope calculated between the
ﬁrst and last time point reported, with retention truncated
at 0%. We calculated a midpoint scenario as the average
of the two. In all scenarios, results were weighted by
cohort size.
Finally, we looked for predictors of retention using
linear regression. Potential predictors included median age
in years (<36 vs. ‡36), % female (<60% vs. ‡60%), median
baseline CD4 count (<100 vs. ‡100), duration of follow-up
(£12 months vs. >12 months), patient payment required
Tropical Medicine and International Health volume 15 suppl. 1 pp 1–15 june 2010
M. P. Fox & S. Rosen Patient retention in antiretroviral therapy programs
6 ª 2010 Blackwell Publishing Ltd, 15 (Suppl. 1), 1–15(yes vs. no), sector (public⁄private⁄other), and year of
initiation of the cohort (<2004 vs. ‡2004). Because we had
only 39 observations, all missing data were coded as
unknown and included in regression analyses, but infer-
ences were only drawn comparing the groups for which we
had data.
Two other potential, program-level predictors of reten-
tion are whether or not the treatment provider undertook
active tracing of patients who were lost and made attempts
to return them to care and how much pre-ART counseling
was given to prepare patients for initiating and maintaining
ART. Practices for preparing patients for ART and tracing
those lost to follow up were not consistently reported,
however, and therefore could not be included in the current
analysis.
Results
Our search identiﬁed 632 papers and abstracts after
removing duplicates. Of these, 491 were excluded on the
basis of title or abstract, and an additional 108 were
excluded after a full text screen and removal of overlapping
cohorts and reports that contained insufﬁcient informa-
tion. Thirty-three sources remained that met our eligibility
criteria (Figure 1), including 22 full text journal articles
and 11 abstracts. These described outcomes for a total of
39 cohorts and 226 307 patients.
Several exclusions from the review and censoring of data
should be noted. First, we omitted reports from the
International epidemiological Databases to Evaluate AIDS
(IeDEA) group that pools data from HIV⁄AIDS treatment
programs. We excluded these reports because many of the
cohorts included in IeDEA’s analyses are described in more
detail in the individual papers and abstracts in our review.
Second, two studies, SA 1 and SA 2, reported outcomes to
48 months, and two studies, Botswana 2 and Cameroon 1,
reported outcomes to 60 months. As these were the only
cohorts reporting to time periods beyond 36 months, we
censored data from these cohorts at the last time period
reported to before 60 months (12 months for Cameroon 1
and 36 months for the remaining 3). And ﬁnally, we
excluded several publications reporting data for cohorts
from Malawi because the most recent report for Malawi, a
conference abstract from July 2009 (Malawi 1), included
data for the entire Malawian national ART program, thus
encompassing the cohorts described in the other papers.
Table 1 describes the characteristics of the cohorts.
Nearly half the cohorts (49%, 19⁄39), representing 81% of
the patients (183,486⁄226,307), were in southern Africa.
The majority of treatment sites were either public sector
(53%) or NGO (41%) facilities. About 35% of the 25
cohorts that provided information on payment reported
that patients had to pay to receive care. The median years
in which cohorts were enrolled for observation and in
which observation ended were 2004 (range 1998–2005)
and 2006 (range 2002–2007).
Table 1 also reports median patient characteristics for
each cohort. Patients were more likely to be female
(median 65%, range 44%–100%) and had a median age at
initiation of ART of 37 (range 34–40). All cohorts that
reported starting CD4 count except one (Kenya 1) had a
median below 200 cells⁄mm
3 (median 113, range 60–203).
For the studies that reported it, the median of the reported
follow-up times was 12 months.
The proportion of patients lost from each cohort at the
end of that cohort’s follow-up stratiﬁed by the cause of
attrition, as well as the total proportion retained at each
site, is shown in Table 2. After weighting for cohort size,
loss to follow-up (LTFU) was the most common cause of
attrition, followed by death (59% and 41% of total
attrition respectively).
Total retention rates at each time point reported are
presented in Table 3. For the 39 cohorts, attrition rates
were reported at only one time point for 24 (61%); the
median time point for these cohorts was 18 months (IQR
12–24 months). Total attrition at 12 months was quite
variable, with a median of 22.6% and a range from 7 to
632 potentially relevant citations
identified through search strategy
(excluding duplicate citations)
491 excluded after first screen of
titels and abstracts:
27 design
39 geographic range 
71 population
354 topic
141 full text of articles or abstracts
screened for eligibility criteria
(90 journal articles, 51 abstracts
108 excluded after full text screen:
26 design
6 follow up period
1 geographic range
3 population
2 topic
47 insufficient information
23 superceded by other sources
33 included in the review
(reporting on 39 patient cohorts)
(22 journal articles, 11 abstracts)
Figure 1 Literature Search and Application of Eligibility Criteria
in a Systematic Review of Retention in Antiretroviral Therapy
Programs in Sub-Saharan Africa.
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Study Code
Median
follow-up
(months) Died (A)
Lost to
follow-up
(B)
Total
attrition
from ART (C)*
Total
retained
(D)*
Transferred
care (E)
Total retained
at original
site (F)*
Botswana 1 10.1 16.8% 5.4% 22.2% 77.8% 0.0% 77.8%
Botswana 2 41.9 19.0% 16.1% 35.1% 64.9% 19.1% 45.8%
Cameroon 1 49.0 28.5% 5.0% 33.4% 66.6% 18.5% 48.0%
Congo 1 9.0– 9.0% 13.1% 22.1% 77.9% 0.0% 77.9%
Cote d’Ivoire 1 7.7 11.2% 13.6% 24.7% 75.3% 3.0% 72.3%
DRC 1 6.0 7.9% 5.5% 13.4% 86.6% 0.0% 86.6%
Ethiopia 1 6.0 18.4% 8.1% 26.5% 73.5% 1.3% 72.2%
Ghana 1 24.0 –– – – – –
Ghana 2 36.0 0.0% 30.8% 30.8% 69.2% 3.4% 65.8%
Kenya 1 15.2§ 0.0% 29.4% 29.4% 70.6% 0.0% 70.6%
Malawi 1 36.0 –– – – – –
Mozambique 1 12.0 5.0% 15.0% 20.0% 80.0% 0.0% 80.0%
Multiple 1 12.0 7.5% 1.2% 8.7% 91.3% 0.0% 91.3%
Multiple 2 14.5– 10.5% 2.8% 13.3% 86.7% 0.0% 86.7%
Nigeria 1 14.6– 6.7% 8.8% 15.5% 84.5% 0.0% 84.5%
Rwanda 1 24.0 –– – – – –
Rwanda 2 14.9– 4.3% 4.5% 8.8% 91.2% 4.0% 87.2%
SA 1 –** – – – – – –
SA 2 37.0– 23.3% 12.0% 35.2% 64.8% 6.4% 58.4%
SA 3 6.0 6.7% 8.6% 15.4% 84.6% 1.1% 83.5%
SA 4a 24.0 9.0% 11.4% 20.4% 79.6% 0.0% 79.6%
SA 4b 36.0 6.0% 7.0% 13.0% 87.0% 0.0% 87.0%
SA 5 36.0 18.0% 5.3% 23.2% 76.8% 3.9% 72.8%
SA 6 –** – – – – – –
SA 7 8.6– 9.2% 2.6% 11.8% 88.2% 4.7% 83.6%
SA 8 24.0 2.0% 11.2% 13.2% 86.8% 0.0% 86.8%
SA 9 8.4– 15.9% 7.4% 23.3% 76.7% 0.0% 76.7%
SA 10a 12.0 2.1% 23.9% 26.0% 74.0% 0.0% 74.0%
SA 10b 12.0 18.9% 26.1% 45.0% 55.0% 0.0% 55.0%
SA 10c 12.0 12.9% 15.1% 28.0% 72.0% 0.0% 72.0%
SA 10d 12.0 7.0% 6.0% 13.0% 87.0% 0.0% 87.0%
Tanzania 1 7.9– 2.5% 12.1% 14.6% 85.4% 0.0% 85.4%
Tanzania 2 10.9 29.7% 9.7% 39.4% 60.6% 10.9% 49.7%
Uganda 1a 12.0 5.0% 19.3% 24.3% 75.7% 0.0% 75.7%
Uganda 1b 24.0 14.7% 17.1% 31.8% 68.2% 0.0% 68.2%
Uganda 2 24.0 18.3% 7.8% 26.1% 73.9% 0.6% 73.3%
Uganda 3 –** – – – – – –
Uganda 4 8.3 5.0% 4.0% 9.0% 91.0% 0.0% 91.0%
Zambia 1 12.0 9.9% 16.9% 26.8% 73.2% 0.0% 73.2%
Simple averages 18.3 10.9% 11.6% 22.5% 77.5% 2.3% 75.1%
Weighted averages 26.3 9.1% 13.0% 22.1% 77.9% 1.1% 76.8%
‘‘—’’ indicates that these data could not be determined from the report.
*Calculations: C = A+B; D = 1 – C; F = D–E.
Rates are based on results after active tracing of patients.
Median not reported but estimated as last time period reported to as >50% of cohort was still retained.
§Median not reported; weighted mean for those lost and those retained by sample size.
–Median not reported; table shows mean follow-up instead.
**Not reported but > 6 months.
Estimated from KM curve.
Weighted by cohort size.
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Study code
Percentage of patients retained at month
6 12 18 24 36 Notes
Botswana 1 – 77.8% – – – 12 month value is at a median of 10.1 months
Botswana 2 – 73.8% – – 63.9% Values estimated from KM estimates of LTFU
and death
Cameroon 1 – 65.0% – – – Values estimated from KM curves counting
LTFU as an event
Congo 1 94.0% 89.0% – – – Survival reported as combined LTFU and death
Cote d’Ivoire 1 – – 64.0% – – 18 month estimate of death and LTFU summed
DRC 1 – 86.7% – – –
Ethiopia 1 72.3% – – – –
Ghana 1 87.0% 81.0% 77.0% 68.0% –
Ghana 2 – 82.5% 74.7% – 68.1% Estimated based on number of patients reporting
for follow-up visits; no deaths reported
Kenya 1 83.0% 74.0% – 65.0% – Estimated using survival analysis. No deaths
reported
Malawi 1 – 77.0% – 70.0% 68.0% Includes stopping ART as attrition
Mozambique 1 86.0% 79.0% – – –
Multiple 1 – 91.3% – – – Attributed total death and LTFU to 12 months
Multiple 2 – – 86.7% – – 18 months value based on mean 15 months
follow-up
Nigeria 1 – – 84.5% – – 18 months value based on mean 15 months
follow-up
Rwanda 1 94.0% 93.0% 91.0% 89.0% –
Rwanda 2 93.0% 91.0% – – – Excluded transfers and stopping ART from
reported attrition
SA 1 89.1% 84.9% 81.3% 80.9% 77.0% Estimates are from nested cohorts
SA 2 76.0% 71.0% 70.0% 68.0% 64.0% Estimated from KM curves; includes patients
transferred as attrition
SA 3 83.5% – – – –
SA 4a – – – 79.6% –
S A 4 b –––– 87.0%
SA 5 87.4% 84.1% – 77.6% 72.8% Includes patients transferred as attrition
S A 6 –––– 74.3% Rate from KM estimates. Weighted average of
pregnant and non-pregnant subjects.
SA 7 – – – 83.6% –
SA 8 – – – 86.8% – Study compared EFV and NVP; rates shown are
for combined cohort.
SA 9 76.7% – – – – 6 month estimate at 8 months
SA 10a – 74.0% – – –
SA 10b – 55.0% – – –
SA 10c – 72.0% – – –
SA 10d – 87.0% – – –
Tanzania 1 – 85.4% – – –
Tanzania 2 – 60.6% – – – 12 month estimate at 11 months
Uganda 1a – 75.7% – – – Data are from retrospective cohort analysis;
excluded transfers and stopping ART from
reported attrition
Uganda 1b – – – 68.2% – Data is from retrospective cohort analysis;
excluded transfers and stopping ART from
reported attrition
Uganda 2 85.0% 77.0% – 73.0% – Includes those who stopped treatment
Uganda 3 – 76.0% – 71.0% –
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change in median attrition (27%) by 24 months, but the
range narrowed slightly, from 11% to 35% in Rwanda 1
and Kenya 1 respectively. By 36 months median attrition
increased to 29.6%, with estimates ranging from 13.0% to
36.1% (in SA 4b and Botswana 2 respectively).
To account for the variable times reported to, in all
analyses presented below we interpolated retention rates at
any time point where an estimate of retention was missing
but a later time point was reported. Fifty estimates of
attrition were interpolated, most at 6, 12, or 18 months
(n = 25, 9, and 11, respectively).
Figure 2a–d show the variation in retention rates at 6,
12, 24 and 36 months using forest plots. Using random
effects meta-analysis to pool the data including the
interpolated time points, we estimated the retention at
Table 3 (Continued)
Study code
Percentage of patients retained at month
6 12 18 24 36 Notes
Uganda 4 91.0% –––– 6 month estimate at 8.3 months
Zambia 1 – 73.2% – – –
Simple averages 85.6% 78.3% 78.6% 75.4% 71.9%
KM, Kaplan-Meier.
36 month retention
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Malawi 1
Ghana 2
Botswana 2
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Rwanda 1 (a) (c)
(b) (d)
Rwanda 2
SA 4b
SA 4a
SA 10d
SA 7
SA 1
SA 5
SA 6
SA 3
SA 10a
SA 10c
SA 9
SA 2
SA 10b
Pooled
0.5 0.6 0.7 0.8
6 month retention
0.9 1.0
Tanzania 2
Ethiopia 1
Cameroon 1
Cote d’lvoir
Zambia 1
Kenya 1
Mozambique 1
Botswana 1
Botswana 2
Uganda 2
Uganda 1a
Uganda 1b
Uganda 3
Malawi 1
Ghana 2
Ghana 1
Nigeria 1
Tanzania 1
SA 8
Multiple 1
Multiple 2
DRC 1
Uganda 4
Congo 1
'
24 month retention
0.60 0.65 0.70 0.75 0.80 0.85 0.90 0.95
Rwanda 1
SA 4b
SA 8
SA 7
SA 1
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SA 4a
SA 2
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Kenya 1
Botswana 2
Uganda 2
Uganda 3
Uganda 1b
Malawi 1
Ghana 2
Ghana 1
'
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12 month retention
0.9 1.0
Rwanda 1
Rwanda 2
SA 4b
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SA 1
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SA 2
SA 10a
SA 10c
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Cameroon 1
Cote d’lvoir
Zambia 1
Kenya 1
Mozambique 1
Botswana 1
Botswana 2
Uganda 2
Uganda 1a
Uganda 1b
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Figure 2 a–d Forest Plots of Reported Retention at 6, 12, 24 and 36 Months after Initiation of Antiretroviral Therapy in Sub-Saharan
Africa*. *Pooled estimates were created using random-effects meta-analysis. Data include both actual reported rates for studies that
reported to each time point and linear interpolation for studies which reported to a later time point but not the current time point.
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12 months to be 80.2% (95% CI: 78.0%–82.4%), at
24 months to be 76.1% (95% CI: 72.4%–79.7%) and at
36 months to be 72.3% (95% CI: 67.4%–76.9%).
We were concerned that studies reporting only to
shorter time points would have higher attrition at those
time points than would studies that reported longer
follow-up. Figure 3 shows retention rates stratiﬁed by last
reported time point. Each time point shows variation in
retention rates, but there is no clear picture of studies
reporting at later time points having higher overall
retention at earlier time points compared to studies
reporting only to earlier time points. While the cohorts
reporting only to 6 and 12 months show lower attrition
with duration of time reported to, suggesting some bias
may exist, the 8 cohorts reporting to 36 months show
sharper declines in the ﬁrst 6–12 months than cohorts
reporting to 24 months.
Using linear regression we found that median starting
CD4 count <100 ()5.8%; 95% CI: )8.9% to )2.7%),
median age <36 (5.7%; 95% CI: )9.2% to )2.2%), and
having <60% females ()9.4%; 95% CI: )13.9% to
)4.9%) were predictive of lower retention rates at
6 months when also adjusting for median follow-up and
year of initiating cohort. For 12 month attrition rates, only
median age <36 ()12.8%; 95% CI: )19.9% to )5.6%),
median CD4 < 100 ()8.8%; 95% CI: )14.5% to )3.1%)
and cohort follow-up £12 months ()8.6%; 95% CI:
)16.9% to )0.4%) were predictive of lower retention
rates. The ﬁnding that median cohort follow-up of
£12 months is associated with lower 12 month retention
rates again suggests that while we did not observe a strong
trend towards studies with longer duration reporting
higher retention rates at comparable time points, some bias
may exist.
To project the potential paths of retention over time, we
conducted three analyses to extrapolate what would have
happened to retention rates at later time points for cohorts
reporting only to earlier time points (Figure 4). The ﬁrst set
of bars shows the best case scenario, in which the latest
observation is carried forward with no further attrition,
while the last set of bars shows a worst case scenario which
assumes that retention continued at a linear rate. There
was little variation in the estimates through 24 months as
the retention midpoint between the two cases is 70.0%
(best-case–worst-case range: 66.7%–73.3%). By
36 months, the retention midpoint between the two cases
is 64.8% (best case-worst case range: 57.5%–72.1%).
Discussion
The global response to scaling up access to antiretroviral
therapy in resource-limited settings has been rapid and
dramatic and represents one of the largest public health
successes in history. By the end of 2008, more than 4
million HIV infected patients had been initiated on life
saving ART (Souteyrand et al. 2009). Even before the
global economic crisis, however, the very large number of
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Figure 4 Projected Retention Rates Over Time in Antiretroviral
Therapy Programs in Sub-Saharan Africa Using Varying
Assumptions*. *Best-case scenario uses last observation carried
forward and assumes no additional attrition after the last time
point reported to. Worst-case scenario assumes a continued linear
decline from the last time point reported to through 36 months.
The mid-point scenario is the average of the best and worst-case
scenarios. Studies are weighted by their sample size.
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Figure 3 Weighted Average Retention Rates Over Time in Anti-
retroviral Therapy Programs in Sub-Saharan Africa*. *Studies
reporting later time points and not earlier ones had the earlier
attrition rates interpolated as described in the methods section and
then weighted by cohort size.
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and budgets. Now, as donors and governments face new
pressure to reduce spending, difﬁcult choices may have to
be made about whether to use limited funds to initiate new
patients on ART or to target funds towards keeping those
already on ART alive and in care.
Our ﬁndings document both the difﬁculties in retaining
patients in care for lifelong treatment, but also the
progress being made in raising overall retention rates.
Our analysis of data from more than 22 500 patients
initiated on ART in sub-Saharan Africa shows that in the
period since our previous analysis, overall retention in
ART programs 3 years after initiating patients on treat-
ment averaged roughly 70% using a random effects
meta-analysis of reported results. This ﬁnding, while not
ideal, is notable in that most of the attrition occurred in
the ﬁrst 2 years on treatment, when both mortality
(Lawn et al. 2008) and loss to follow-up are known to
be high. After the ﬁrst 24 months, attrition averaged
about 5% per year.
The retention rate at 24 months we estimated in this
analysis, 76% using meta-analysis, was higher than that
estimated in our earlier review, which only analysed studies
through 2 years. In that analysis we estimated 62%
retention by 2 years. That analysis did not use a meta-
analysis approach as was performed here but instead used
a weighted average approach. This suggests that overall
attrition by 2 years may be slowing as experience of scaling
up ART accumulates and treatment programs mature and
are better able to track patients. The greater attention to
measuring and understanding loss to follow-up that is
reﬂected in the large number of publications on this topic
in recent years may be paying off as programs invest in
interventions to track missing patients and return them to
care.
We found substantial variation in retention rates
reported over time but few predictors of overall retention
that explain these differences and provide guidance on
what determines attrition rates. While we were only able to
estimate predictors of attrition in the ﬁrst year after
treatment initiation, we found that low median CD4 count
and having fewer females as part of the cohort were
predictive of higher attrition. Programmes with low
median CD4 count would be expected to have more overall
attrition because of mortality. As ART programmes
expand, initiating patients with higher CD4 counts could
lead to both improved outcomes on treatment as well as
less overall attrition. Indeed, while our current analysis
showed a very similar median initiating CD4 count to our
previous analysis (128 in the current analysis vs. 132 in the
previous analysis), others have found an increasing starting
CD4 count over time (Keiser et al. 2008). Our analysis
suggests that any such increases in baseline CD4 count may
also be associated with increases in retention.
Loss to follow-up constituted the highest contributor to
overall attrition, as was the case in our previous report. As
the number of facilities offering ART expands, more of the
patients reported as lost to follow-up may in fact have
transferred informally to another facility. In our analysis,
among studies which reported any transfers, about 7% of
all patients who initiated care transferred to another
facility. While most countries ﬁnd it difﬁcult to track
patients from one facility to another, developing reliable
referral systems that document transfers is essential to
evaluating overall programmatic effectiveness.
For those patients who are lost but do not seek care
elsewhere, mortality is expected to be high (Mocroft et al.
1997; Morgan et al. 2002; Badri et al. 2006). Brinkhof
et al. (2009) conducted a systematic review of outcomes
among patients lost from treatment programmes and
estimated that about 40% (95% CI: 33%–48%) of LTFU
patients had died, with much of the mortality occurring in
the ﬁrst 6 months after being lost to follow-up. Making
efforts to get these patients back into care is important to
the overall success of ART programmes, and developing
ways to track and locate lost patients is essential to proper
programme evaluation (Bisson et al. 2007). To further
evaluate programmes, when available, method such as
cross referencing with vital registration systems (Anglaret
et al. 2004; Fairall et al. 2008) or adjusting mortality
estimates statistically (Geng et al. 2008; Yiannoutsos et al.
2008; Fox et al. 2010) should allow for better estimates
of programme impact as well as appropriate targeting of
resources towards patient retention.
Our ﬁndings should be interpreted in the light of several
limitations. First, we used data collected and reported by
ART programs. Some misclassiﬁcation of treatment out-
comes likely existed, although we have little reason to
believe these misclassiﬁcations would be anything more
than random. Second, we integrated information from
studies that reported at many different time points, and not
all reported at a time point we were interested in. In these
cases we applied the retention rate to the nearest time
point, but this may have caused some bias in our overall
estimates. Third, we were not able to determine whether
the deﬁnition of LTFU used in speciﬁc studies inﬂuenced
overall retention rates because of the variability in deﬁni-
tions, which made it impossible in many cases to determine
how long patients were absent from the clinic before being
classiﬁed as lost.
Fourth, systematic reviews can be subject to publication
bias. Programmes managing cohorts with higher attrition
rates might be less interested in publishing their results, and
this would likely lead to an underestimation of overall
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be both better able to retain patients in care and to conduct
and publish research, particularly long-term analyses
requiring consistent data collection and strong data anal-
ysis capacity. Both of these phenomena would lead to the
bias that we found in our previous analysis, in which
cohorts with higher attrition rates are more likely to
publish outcomes only at earlier time points. We saw some
evidence for this in the current analysis, as the average
6-month retention rates were lowest for studies that only
reported to 6 months compared to the average 6-month
retention rates from cohorts also reporting to later time
periods. Our sensitivity analysis shows that if cohorts
reporting only to earlier time points had continued along at
the same rate of attrition as they reported at those earlier
points, overall retention would be as low as 67% at
24 months and as low as 58% by the end of 36 months.
While this sensitivity analysis may overestimate attrition,
even our midpoint scenario (averaging the best- and worst-
case scenarios) showed that overall attrition by 36 months
is likely underestimated when using only published infor-
mation.
Finally, our data were not extracted in duplicate as is
recommended by the Cochrane Collaboration. We instead
used single data extraction. This could have resulted in
some studies being missed that potentially could have met
the inclusion criteria.
In conclusion, we found that overall attrition by
24 months has likely decreased slightly since our earlier
report, with overall retention by 24 months averaging
70%–77% and overall retention by 36 months averaging
65%–72%. Programmes initiating patients at lower CD4
counts also had higher rates of attrition than those
initiating patients with higher CD4 counts. Active tracing
of lost patients to return them to care and determine their
vital status if not returned should be prioritized so as to
keep overall retention high and to appropriately evaluate
treatment programmes.
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